EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vertex Pharmaceuticals's enterprise value is $66,521 Mil.
Vertex Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $8,350 Mil. Therefore, Vertex Pharmaceuticals's EV-to-Revenue for today is 7.97.
The historical rank and industry rank for Vertex Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
VRTX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 4.24 Med: 13.15 Max: 52.73
Current: 7.98
During the past 13 years, the highest EV-to-Revenue of Vertex Pharmaceuticals was 52.73. The lowest was 4.24. And the median was 13.15.
VRTX's EV-to-Revenue is ranked better than 58.67% of 934
companies
in the Biotechnology industry
Industry Median: 11.00
vs VRTX: 7.98
As of today (2022-08-12), Vertex Pharmaceuticals's stock price is $293.25.
Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $32.33. Therefore, Vertex Pharmaceuticals's PS Ratio for today is 9.07.
Vertex Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for Vertex Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Vertex Pharmaceuticals Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
EV-to-Revenue
14.66
13.03
12.87
8.97
6.51
Vertex Pharmaceuticals Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
EV-to-Revenue
6.95
5.66
6.51
7.47
7.63
Competitive Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's EV-to-Revenue falls into.
Vertex Pharmaceuticals's current Enterprise Value is $66,521 Mil.
Vertex Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,350 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals's share price for today is $293.25.
Vertex Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
1.09(0.37%) Volume: 168,937 11:05AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VRTX has been successfully added to your 
